Eyenovia Inc. 2025年季度报告

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large acceleratedfiler,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any news or revised financial accounting standards provided pursuant to Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act). EYENOVIA,INC. FORM10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 PARTI - FINANCIAL INFORMATION PARTI– FINANCIAL INFORMATION EYENOVIA,INC. EYENOVIA,INC. Condensed Statements of Changes in Stockholders’ (Deficiency) Equity(unaudited) The accompanying notes are an integral part of these condensed financial statements. EYENOVIA,INC. Condensed Statements of Cash Flows, continued(unaudited) EYENOVIA, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note1– Business Organization, Nature of Operations and Basis of Presentation Eyenovia, Inc., (“Eyenovia” or the “Company”) is an ophthalmic technology company developing a proprietaryOptejet® topical ophthalmic medication dispensing platform. In November 2024, the Company received anegative clinical trial result in its development-stage drug-device combination product, MicroPine. As a result, theCompany restructured, minimized expenses and engaged with an investment bank to explore strategic options in The accompanying unaudited condensed financial statements have been prepared in accordance with accountingprinciples generally accepted in the United States of America (“U.S. GAAP”) for interim financial informationand with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all ofthe information and disclosures required by U.S. GAAP for complete financial statements. In the opinion ofmanagement, such statements include all adjustments (consisting only of normal recurring items) which areconsidered necessary for a fair presentation of the condensed financial statements of the Company as of March 31,2025 and for the three months ended March 31, 2025 and 2024. The results of operations for the three monthsended March 31, 2025 are not necessarily indicative of the operating results for the full year ending December 31, Basis of Presentation On January 31, 2025, the Company effected a reverse stock split of its common stock at a ratio of1–for-80(the“Reverse Split”). Upon the effectiveness of the Reverse Split, every 80 issued shares of common stock werereclassified and combined into one share of common stock. In addition, the number of shares of common stockissuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionallydecreased, and the corresponding conversion price or exercise price was proportionally increased. No fractionalshares were issued as a result of the Reverse Split. Stockholders who would otherwise have been entitled to Note 2 – Going Concern The Company expects to continue to incur cash outflows from operations for the near future. These circumstancesraise substantial doubt about the Company’s ability to continue as a going concern for at least one year from thedate that these financial statements are issued. Implementation of the Company’s plans and its ability to continueas a going concern will depend upon the Company’s ability to generate sufficient recurring revenues, theCompany’s ability to raise further capital, through the sale of additional equity or debt securities or the completion EYENOVIA, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note3– Summary of Significant Accounting Policies The Company disclosed its significant accounting policies in Note 2 – Summary of Significant AccountingPolicies included in the 2024 Form 10-K. There have been no material changes to the Company’s significant Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cashequivalents in the condensed financial statements. As of March 31, 2025, the Company hadnoTreasury bills with The Company has cash deposits in financial institutions that, at times, may be in excess of Federal DepositInsurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts andperiodically evaluates the creditworthiness of its financial institutions. As of March 31, 2025, the Company had Note 4 – Net Loss Per Share of Common Stock Basic net loss per share of common stock is computed by dividing net loss by the weighted average number ofshares of common stock outstanding during the period, plus fully vested shares that are subject to issuance forlittle or no monetary consideration. Diluted loss per